Johnson & Johnson $JNJ Stock: DMKC Advisory Services LLC Trims Holdings

DMKC Advisory Services LLC trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 36.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,650 shares of the company’s stock after selling 9,361 shares during the quarter. Johnson & Johnson comprises 1.1% of DMKC Advisory Services LLC’s portfolio, making the stock its 23rd largest holding. DMKC Advisory Services LLC’s holdings in Johnson & Johnson were worth $4,408,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Cpwa LLC lifted its stake in shares of Johnson & Johnson by 36.5% in the 3rd quarter. Cpwa LLC now owns 3,934 shares of the company’s stock worth $1,037,000 after acquiring an additional 1,051 shares during the period. Global Wealth Management Investment Advisory Inc. increased its stake in shares of Johnson & Johnson by 2.7% during the third quarter. Global Wealth Management Investment Advisory Inc. now owns 27,401 shares of the company’s stock valued at $7,254,000 after acquiring an additional 721 shares during the period. 71 West Capital Partners increased its stake in shares of Johnson & Johnson by 3.5% during the third quarter. 71 West Capital Partners now owns 16,276 shares of the company’s stock valued at $4,309,000 after acquiring an additional 544 shares during the period. Flynn Zito Capital Management LLC raised its holdings in Johnson & Johnson by 3.3% during the third quarter. Flynn Zito Capital Management LLC now owns 3,310 shares of the company’s stock worth $876,000 after purchasing an additional 106 shares in the last quarter. Finally, Channel Wealth LLC raised its holdings in Johnson & Johnson by 1.1% during the third quarter. Channel Wealth LLC now owns 4,687 shares of the company’s stock worth $1,241,000 after purchasing an additional 50 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $281.86 on Tuesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. The firm’s 50 day moving average is $266.18 and its 200-day moving average is $248.62. Johnson & Johnson has a 12-month low of $185.12 and a 12-month high of $282.73. The stock has a market capitalization of $678.53 billion, a P/E ratio of 42.71, a P/E/G ratio of 2.73 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.53 by $0.06. The business had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business’s quarterly revenue was up 5.9% on a year-over-year basis. During the same period in the prior year, the business earned $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities research analysts anticipate that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 1.9%. Johnson & Johnson’s dividend payout ratio is currently 81.21%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 15,000 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares of the company’s stock, valued at $51,210,615.36. This trade represents a 7.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the transaction, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.16% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Citigroup increased their price target on Johnson & Johnson from $298.00 to $303.00 and gave the company a “buy” rating in a research note on Monday, October 5th. HSBC lifted their price target on Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Johnson Rice downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, October 21st. Bank of America restated a “neutral” rating and issued a $278.00 price objective on shares of Johnson & Johnson in a report on Tuesday, September 29th. Finally, Weiss Ratings cut Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a research note on Friday, October 23rd. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $275.92.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: In a first-in-human Phase 1 study, the investigational pasritamig–JNJ-9401 combination produced a PSA reduction of at least 50% in 11 of 15 patients with advanced prostate cancer; nearly half had reductions of at least 90%. J&J reported an encouraging safety profile and said the regimen is advancing toward Phase 3, though the small early-stage study carries substantial uncertainty. Article: Johnson & Johnson reports 73% PSA response rate
• Positive Sentiment: ICOTYDE (icotrokinra) met the primary endpoint in a Phase 3 trial in biologic-naive patients with psoriatic arthritis, supporting the potential of this once-daily oral treatment. Article: ICOTYDE meets primary endpoint in Phase 3 study
• Positive Sentiment: J&J also presented new nipocalimab data in Sjögren’s disease and reported positive results for autoimmune therapies at a medical meeting, adding to the pipeline’s potential, although the reports provide limited detail on commercial impact. Article: New Phase 2 nipocalimab study data
• Negative Sentiment: ETF investors were net sellers of J&J shares on Nov. 5, a modestly negative flow signal that predates the latest trial announcements. Article: ETFs are net sellers of Johnson & Johnson

Johnson & Johnson Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.